Treatment outcomes and cognitive function following electroconvulsive therapy in patients with severe depression

Table 2 Changes in hamilton depression evaluation scale score and secondary outcomes from baseline to 12 wk, n (%)

Outcome	ECT group (n = 102)	Non-ECT group (n = 102)	P value
HDRS score	-19.6 ± 6.4 (-69)	-14.2 ± 7.2 (-50)	< 0.001
WHOQOL-BREF score	+15.4 ± 8.7 (+37)	+9.2 ± 7.9 (+21)	< 0.001
MoCA score	+2.6 ± 1.4 (+10)	+1.0 ± 1.2 (+4)	< 0.001
BDNF level (ng/mL)	-12.8 ± 4.6 (-69)	-18.6 ± 5.8 (-98)	< 0.001
IL-6 level (pg/mL)	+2.2 ± 0.9 (+65)	+3.4 ± 1.2 (+97)	< 0.001
Cortisol level (ng/mL)	-0.2 ± 3.8 (-2)	-0.1 ± 4.1 (-1)	0.92

Values are depicted as average ± deviation with percentage alteration in brackets. ECT: Electroconvulsive treatment; HDRS: Hamilton depression evaluation scale; WHOQOL-BREF: World Health Organization Quality of Life-BREF Assessment; MoCA: Montreal cognitive evaluation; BDNF: Brain-derived neurotrophic factor; IL-6: Interleukin-6.